Umbilical Cord Blood CD34+ Hematopoietic Stem Cell-Derived Natural Killer Cells in Acute Myeloid Leukaemia – A Phase I Clinical Study
- Demonstrating safety and feasibility of umbilical cord blood–derived CD34 NK cell therapy with no dose-limiting toxicities or GVHD
- Showcasing in vivo persistence, activation, and cytotoxicity confirming biological activity in AML patients
- Highlighting preliminary clinical responses with blast reduction and MRD clearance supporting next-phase development